Viking Thera VKTX

$35.56 -1.19 (-3.24%)

Valuation

Market cap
4,148,181,000
Revenue TTM
$0
Net income TTM
$-359,640,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
13,579,101
Avg volume
3,841,694
Day's range
$35.10 – $39.05
Shares out
116,653,000
Stochastic %K
49%
Beta
0.69
Analysts
Strong Sell
Price target
$91.50

Price

Company profile

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as...

Show more

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Phone
858 704 4660
Website
https://www.vikingtherapeutics.com
Address
9920 Pacific Heights Boulevard, Suite 350, San Diego, United States

Latest news

Stocktwits

Freakyguy666 Sep 27, 10:50 PM
$VKTX absent news or BO rumors, 2-3 weeks to clear the new supply of shares.
0 replies
spodero Sep 27, 10:34 PM
$VKTX Helpful chart, thanks. Presumably numbers are all placebo-adjusted. As you implied, one problem with cross-trial comparisons in obesity is that you can always bump up weight loss if you bump up side effects. It comes down to side effects per unit weight loss and dollar cost per unit weight loss, so charts of weight loss vs. time never tells the real story (and the other charts aren’t really available). Two takeaways from the chart. First (and obviously), this is going to be incredibly competitive with many approved drugs. Genuine differences between drugs will be swamped by perception. Absolutely nothing I’ve seen since the P2 rollout suggests that BL won’t be a boy among men in this battle. Even with what may be the best drug, I don’t think 2735 will be a huge blockbuster if they GIA. A few billion per year if GIA? Sure. $10B GIA? I don’t think so. $10B/yr if partnered? Yes. Second, MariTide is shit. Amgen really ought to pull the plug on it and make VKTX a good offer.
1 replies
VentureBack Sep 27, 10:31 PM
$VKTX all should reshare unless you’re trying to buy more 🤣
0 replies
PensionPulse Sep 27, 10:07 PM
$VKTX All these articles are generated by a really dumb AI bot or written by a complete moron. I literally cringe reading this nonsense
0 replies
Cache_Money Sep 27, 9:51 PM
$VKTX Just remember that institutions saw $35 as a very attractive entry point for long-term positions. It’s very likely the de-risked data on VK2735 plus the new influx of capital will attract previously hesitant investors. Here is the way this will most likely play out: over the next few days, swing traders will aggressively flip the stock whenever it starts climbing. Institutions are going to take advantage of this by putting in stealth buys of small chunks whenever the stocks gets close to the $35 floor to avoid spiking the price. They don’t want you, the retail investor, to know they want your shares. After about a week the swing trades will start to wash out, having sold many of their shares to both these funds and new retail longs that are hearing the news late. The stock price may slowly climb. At this point ANY good news - for instance the Q4 phase 3 oral trial initiation, or another buyout rumor - will send this sharply higher because of lack of supply.
1 replies
Number_4 Sep 27, 9:48 PM
$VKTX I have never blocked as many people as I have the last 3 days. This forum is going downhill fast.
0 replies
ians Sep 27, 9:44 PM
$VKTX 1yr ROI (+41.73%) SPY 1yr ROI (+17.2%) PFE 1yr ROI (+21.4%) NVO 1yr ROI (-30.7%) Not only did VKTX beat SPY, it also beat PFE, validating my decision last year to sell off all my remaining PFE shares(after Bourla's lame MTSR BO) & to transfer all proceeds into VKTX.👍 And a year from now (with +ve P3 VANQUISH readouts) I'm betting if NVO doesn't BO or at the very least partner with VKTX by then, its stock price will be left further in the dust. 🤷‍♂️ It's not too late NVO to save yourself with BIC VK2735 🥇☘️💎 https://stocktwits.com/ians/message/629572169 https://stocktwits.com/ians/message/664743162
0 replies
AnJaMi Sep 27, 9:14 PM
$VKTX 49 https://youtu.be/kldHuo8ZGxo?si=dUfLMakH2MT81Dp4
0 replies